Skip to content
Clinical

27 Oct 2026 · 3 min read

A Step Forward for Cystic Fibrosis Genetic Testing in Sri Lanka

A new CFTR gene panel aims to bring more comprehensive genetic testing closer to local patients and families.

Kusal SathsaraJunior Bioinformatician
A new CFTR gene panel aims to bring more comprehensive genetic testing closer to local patients and families.

Why cystic fibrosis matters

Cystic fibrosis (CF) is an inherited condition that can affect several organs, especially the lungs and digestive system. It is caused by changes in the CFTR gene. When the CFTR protein does not work properly, mucus can become thick and sticky, contributing to repeated lung infections and digestive problems.

More than 160,000 people are estimated to be living with CF worldwide. Although the condition is often associated with people of European ancestry, it affects people from many backgrounds. More than 2,000 CFTR variants have been reported, and the variants found in one population may differ from those found in another.

Why broader testing is important in Sri Lanka

Cystic fibrosis remains under-diagnosed in Sri Lanka, and reliable national data on its frequency and the CFTR variants present in the population are limited. A previous study of 10 unrelated Sri Lankan patients identified seven CF-causing mutations (Indika et al., 2019), highlighting the diversity of variants found locally.

This matters because a test that checks only a small number of common mutations may not identify every relevant variant. A broader approach can help build a clearer picture of the changes present in the CFTR gene.

Why broader testing is important in Sri Lanka

A locally developed CFTR gene panel

“27 CFTR Coding Exons Covered | 1,789+ Clinically Relevant Hotspot Database”

The Genelabs X research team has developed a targeted genetic panel designed to analyse all 27 coding exons of the CFTR gene, along with nearby exon–intron boundaries. The panel is supported by a curated database of more than 1,789 clinically relevant CFTR variants drawn from established genetic resources.

What could this mean for patients and families?

More complete genetic information may help clinicians investigate suspected CF, support genetic counselling, and identify relatives who may benefit from carrier testing. Knowing a person’s CFTR variants may also inform discussions about whether certain variant-specific treatments could be suitable. Results must always be interpreted alongside clinical findings by qualified healthcare professionals.

Most importantly, this panel provides a cost-effective solution for comprehensive CFTR genetic analysis, supporting more accessible and efficient genetic testing

A practical step forward

The panel is intended to offer a focused, more comprehensive option between testing for selected mutations and broader approaches such as whole-exome sequencing.

Developing this panel is a step towards strengthening genetic diagnostic capacity in Sri Lanka. For patients and families, better genetic information can support more informed conversations, clearer counselling and decisions about care.

“The goal is to move beyond asking, “Is this one specific mutation present?” and towards asking, “Which clinically relevant CFTR variants may be present?”

About the study

This article is based on the study “Development and validation of a next-generation sequencing assay for comprehensive CFTR gene analysis in clinical diagnostics,” presented at BioMed Frontiers 2026: International Conference on Biomedical Innovation.

Reference

Indika, N. L. R., Vidanapathirana, D. M., Dilanthi, H. W., et al. (2019). Phenotypic spectrum and genetic heterogeneity of cystic fibrosis in Sri Lanka. BMC Medical Genetics, 20, Article 89. https://doi.org/10.1186/s12881-019-0815-x

Written by

Kusal Sathsara

Junior Bioinformatician

View All Insights
  • Paediatric Care

    Research

    From Diagnostic Uncertainty to Answers: How Genomic Sequencing Is Transforming Paediatric Care

    How advanced DNA analysis is helping identify rare genetic conditions in children, inform clinical decisions, and support families in Sri Lanka.

    Read More
  • WORKSHOP ON BIOINFORMATICS FOR GENOMIC MEDICINE 2025

    Training

    From Training to Patient Care: Advancing Genomic Medicine in Sri Lanka

    Genelabs Medical (Pvt) Ltd, together with the U.S. Embassy in Sri Lanka, organised the Bioinformatics for Genomic Medicine 2025 training programme.

    Read More
  • Decoding Dengue in Sri Lanka: From Genomic Discovery to National Impact

    Research

    Decoding Dengue in Sri Lanka: From Genomic Discovery to National Impact

    Collaborative research initiative

    Read More

Stay informed

New research and programmes in your inbox.

A short monthly update. No spam, unsubscribe anytime.